Article Text

Download PDFPDF
CASE REPORT
Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved?
  1. Sofiya Bedo Latifyan1,2,
  2. Michel Vanhaeverbeek2,3,
  3. Jean Klastersky1,2
  1. 1Institut Jules Bordet, Brussels, Belgium
  2. 2Université Libre de Bruxelles, Brussels, Belgium
  3. 3Centre Hospitalo-Universitaire de Charleroi, Charleroi, Belgium
  1. Correspondence to Dr Sofiya Bedo Latifyan, sofia.latifyan{at}bordet.be

Summary

Tumour-associated osteomalacia is a paraneoplastic syndrome caused by renal phosphate wasting, leading to severe hypophosphataemia. Excess of circulating fibroblast growth factor 23 (FGF23) is the likely cause, acting via the FGF23/α-Klotho coreceptor, a critical regulator of phosphate metabolism. The other possible effects of that complex in humans are still under investigation. We present a case of an 84-year-old Belgian man, presenting prostate cancer with bone metastases. From June 2010 to March 2013, he presented three episodes of disease progression. From January 2012, the patient developed a progressively marked dorsal kyphosis with significant hypophosphataemia. The calculated TRP (tubular reabsorption of phosphate) was decreased and the FGF23 increased. Mid-March 2013, the patient died after a profound unconsciousness due to hypoglycaemia with hypothermia. We hypothesised that the two paraneoplastic manifestations of this patient (tumour-associated osteomalacia and refractory hypoglycaemia) were due to one cause chain with two main nodes—FGF23 and its coreceptor Klotho..

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.